Vilazodone, a Novel SSRI Antidepressant with 5-HT1A Partial Agonist Properties: Diminished Potentiation of Chronic Oral Methylphenidate-Induced Dynorphin Expression in the Striatum in Adolescent Male Rats.
Dynorphin
Fluoxetine
Gene Expression
Methylphenidate
Psychostimulant
SSRI
Striatum
Vilazodone
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
received:
15
05
2024
accepted:
18
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
aheadofprint
Résumé
Selective serotonin reuptake inhibitor (SSRI) antidepressants such as fluoxetine are used in combination with the medical psychostimulant methylphenidate (Ritalin) in a variety of treatments in children and adults. Unintended co-exposure to these psychotropic medications also occurs in patients on SSRIs who abuse methylphenidate as a "cognitive enhancer" or recreational drug. Preclinical research shows that SSRIs such as fluoxetine when given in conjunction with methylphenidate potentiate addiction-related gene regulation by methylphenidate in the striatum, consistent with the known facilitatory role for serotonin in psychostimulant-induced neuronal and behavioral changes. Moreover, fluoxetine combined with methylphenidate also facilitated subsequent acquisition of cocaine self-administration in adolescent rats, suggesting an increased addiction liability for methylphenidate. In the present study, we investigated the impact of a novel SSRI, vilazodone, on methylphenidate-induced gene regulation in adolescent male rats. In contrast to prototypical SSRIs such as fluoxetine, vilazodone also acts as a partial 5-HT1A serotonin receptor agonist and is thus proposed to temper serotonin input to the striatum. We compared the effects of chronic treatment (4 weeks) with vilazodone (10 mg/kg, twice daily) with those of fluoxetine (5 mg/kg, twice daily) on striatal dynorphin expression induced by oral methylphenidate treatment (30/60 mg/kg/day in drinking water, 8 h access daily). Our results demonstrate that, in contrast to fluoxetine, vilazodone had minimal or no potentiating effects on methylphenidate-induced dynorphin expression. This diminished impact on gene regulation was seen throughout the striatum, including the nucleus accumbens, where increased dynorphin expression has previously been associated with various aspects of addiction. Our findings suggest that vilazodone may serve as a better adjunct SSRI with reduced addiction-facilitating properties.
Identifiants
pubmed: 39466575
doi: 10.1007/s12035-024-04569-8
pii: 10.1007/s12035-024-04569-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS (2007) Trends in medication treatment for ADHD. J Atten Disord 10:335–342
pubmed: 17449832
Kollins SH (2008) ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. J Atten Disord 12:115–125
pubmed: 18192623
Swanson JM, Wigal TL, Volkow ND (2011) Contrast of medical and nonmedical use of stimulant drugs, basis for the distinction, and risk of addiction: comment on Smith and Farah (2011). Psychol Bull 137:742–748
pubmed: 21859175
pmcid: 3187625
DSMMD (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Arlington, VA
Rushton JL, Whitmire JT (2001) Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998. Arch Pediatr Adolesc Med 155:560–565
pubmed: 11343498
Safer DJ, Zito JM, DosReis S (2003) Concomitant psychotropic medication for youths. Am J Psychiatry 160:438–449
pubmed: 12611822
Waxmonsky J (2003) Assessment and treatment of attention deficit hyperactivity disorder in children with comorbid psychiatric illness. Curr Opin Pediatr 15:476–482
pubmed: 14508296
Spencer TJ (2006) ADHD and comorbidity in childhood. J Clin Psychiatry 67 Suppl 8:27–31
Lavretsky H, Kim MD, Kumar A, Reynolds CF (2003) Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J Clin Psychiatry 64:1410–1414
pubmed: 14728100
Nelson JC (2007) Augmentation strategies in the treatment of major depressive disorder. Recent findings and current status of augmentation strategies. CNS Spectr 12 Suppl 22:6–9
Ishii M, Tatsuzawa Y, Yoshino A, Nomura S (2008) Serotonin syndrome induced by augmentation of SSRI with methylphenidate. Psychiatry Clin Neurosci 62:246
pubmed: 18412855
Ravindran AV, Kennedy SH, O’Donovan MC, Fallu A, Camacho F, Binder CE (2008) Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 69:87–94
pubmed: 18312042
Csoka A, Bahrick A, Mehtonen OP (2008) Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. J Sex Med 5:227–233
pubmed: 18173768
Benson K, Flory K, Humphreys KL, Lee SS (2015) Misuse of stimulant medication among college students: a comprehensive review and meta-analysis. Clin Child Fam Psychol Rev 18:50–76
pubmed: 25575768
SAMHSA (2015) Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. NSDUH Series H-50, HHS Publication No (SMA) 15-4927. https://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf . Accessed 24 Oct 2024
Compton WM, Han B, Blanco C, Johnson K, Jones CM (2018) Prevalence and correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the United States. Am J Psychiatry 175:741–755
pubmed: 29656665
pmcid: 6070393
Iversen L (2006) Neurotransmitter transporters and their impact on the development of psychopharmacology. Br J Pharmacol 147(Suppl 1):S82–88
pubmed: 16402124
pmcid: 1760736
Carlezon WAJ, Konradi C (2004) Understanding the neurobiological consequences of early exposure to psychotropic drugs: linking behavior with molecules. Neuropharmacology 47:47–60
pubmed: 15464125
pmcid: 4204484
Carrey N, Wilkinson M (2011) A review of psychostimulant-induced neuroadaptation in developing animals. Neurosci Bull 27:197–214
pubmed: 21614102
pmcid: 5560359
Marco EM, Adriani W, Ruocco LA, Canese R, Sadile AG, Laviola G (2011) Neurobehavioral adaptations to methylphenidate: the issue of early adolescent exposure. Neurosci Biobehav Rev 35:1722–1739
pubmed: 21376076
Van Waes V, Steiner H (2015) Fluoxetine and other SSRI antidepressants potentiate addiction-related gene regulation by psychostimulant medications. In: Pinna G (ed) Fluoxetine: pharmacology, mechanisms of action and potential side effects. Nova Science, Hauppauge, NY, pp 207–225
Adriani W, Leo D, Guarino M, Natoli A, Di Consiglio E, De Angelis G, Traina E, Testai E, Perrone-Capano C, Laviola G (2006) Short-term effects of adolescent methylphenidate exposure on brain striatal gene expression and sexual/endocrine parameters in male rats. Ann N Y Acad Sci 1074:52–73
pubmed: 17105903
Steiner H, Van Waes V (2013) Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants. Prog Neurobiol 100:60–80
pubmed: 23085425
Berke JD, Paletzki RF, Aronson GJ, Hyman SE, Gerfen CR (1998) A complex program of striatal gene expression induced by dopaminergic stimulation. J Neurosci 18:5301–5310
pubmed: 9651213
pmcid: 6793476
Yuferov V, Nielsen D, Butelman E, Kreek MJ (2005) Microarray studies of psychostimulant-induced changes in gene expression. Addict Biol 10:101–118
pubmed: 15849024
Heiman M, Schaefer A, Gong S, Peterson JD, Day M, Ramsey KE, Suárez-Fariñas M, Schwarz C, Stephan DA, Surmeier DJ, Greengard P, Heintz N (2008) A translational profiling approach for the molecular characterization of CNS cell types. Cell 135:738–748
pubmed: 19013281
pmcid: 2696821
Yano M, Steiner H (2007) Methylphenidate and cocaine: the same effects on gene regulation? Trends Pharmacol Sci 28:588–596
pubmed: 17963850
Volkow ND, Wang GJ, Fowler JS, Logan J, Franceschi D, Maynard L, Ding YS, Gatley SJ, Gifford A, Zhu W, Swanson JM (2002) Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 43:181–187
pubmed: 11793423
Yano M, Beverley JA, Steiner H (2006) Inhibition of methylphenidate-induced gene expression in the striatum by local blockade of D1 dopamine receptors: interhemispheric effects. Neuroscience 140:699–709
pubmed: 16549270
Alburges ME, Hoonakker AJ, Horner KA, Fleckenstein AE, Hanson GR (2011) Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment. J Neurochem 117:470–478
pubmed: 21323925
Ahmed R, Blum K, Thanos PK (2023) Epigenetic effects of psychoactive drugs. Curr Pharm Des 29:2124–2139
pubmed: 37415372
Klein SR, Blum K, Gold MS, Thanos PK (2024) Chronic methylphenidate effects on brain gene expression: an exploratory review. Psychol Res Behav Manag 17:577–592
pubmed: 38379637
pmcid: 10876479
Morris BJ, Reimer S, Hollt V, Herz A (1988) Regulation of striatal prodynorphin mRNA levels by the raphe-striatal pathway. Brain Res 464:15–22
pubmed: 3179742
Bhat RV, Baraban JM (1993) Activation of transcription factor genes in striatum by cocaine: role of both serotonin and dopamine systems. J Pharmacol Exp Ther 267:496–505
pubmed: 8229780
Walker PD, Capodilupo JG, Wolf WA, Carlock LR (1996) Preprotachykinin and preproenkephalin mRNA expression within striatal subregions in response to altered serotonin transmission. Brain Res 732:25–35
pubmed: 8891265
Lucas JJ, Segu L, Hen R (1997) 5-Hydroxytryptamine1B receptors modulate the effect of cocaine on c-fos expression: converging evidence using 5-hydroxytryptamine1B knockout mice and the 5-hydroxytryptamine1B/1D antagonist GR127935. Mol Pharmacol 51:755–763
pubmed: 9145913
Horner KA, Adams DH, Hanson GR, Keefe KA (2005) Blockade of stimulant-induced preprodynorphin mRNA expression in the striatal matrix by serotonin depletion. Neuroscience 131:67–77
pubmed: 15680692
Pan D, Gatley SJ, Dewey SL, Chen R, Alexoff DA, Ding YS, Fowler JS (1994) Binding of bromine-substituted analogs of methylphenidate to monoamine transporters. Eur J Neurosci 264:177–182
Kuczenski R, Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68:2032–2037
pubmed: 9109529
Segal DS, Kuczenski R (1999) Escalating dose-binge treatment with methylphenidate: role of serotonin in the emergent behavioral profile. J Pharmacol Exp Ther 291:19–30
pubmed: 10490882
Muller CP, Huston JP (2006) Determining the region-specific contributions of 5-HT receptors to the psychostimulant effects of cocaine. Trends Pharmacol Sci 27:105–112
pubmed: 16406129
Cunningham KA, Anastasio NC (2014) Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. Neuropharmacology 76:460–478
pubmed: 23850573
Alter D, Beverley JA, Patel R, Bolaños-Guzmán CA, Steiner H (2017) The 5-HT1B serotonin receptor regulates methylphenidate-induced gene expression in the striatum: Differential effects on immediate-early genes. J Psychopharmacol 31:1078–1087
pubmed: 28720013
pmcid: 5540766
Castanon N, Scearce-Levie K, Lucas JJ, Rocha B, Hen R (2000) Modulation of the effects of cocaine by 5-HT1B receptors: a comparison of knockouts and antagonists. Pharmacol Biochem Behav 67:559–566
pubmed: 11164086
Van Waes V, Beverley J, Marinelli M, Steiner H (2010) Selective serotonin reuptake inhibitor antidepressants potentiate methylphenidate (Ritalin)-induced gene regulation in the adolescent striatum. Eur J Neurosci 32:435–447
pubmed: 20704593
pmcid: 2921647
Beverley JA, Piekarski C, Van Waes V, Steiner H (2014) Potentiated gene regulation by methylphenidate plus fluoxetine treatment: long-term gene blunting (Zif268, Homer1a) and behavioral correlates. Basal Ganglia 4:109–116
pubmed: 25530939
pmcid: 4267118
Lamoureux L, Beverley JA, Marinelli M, Steiner H (2023) Fluoxetine potentiates methylphenidate-induced behavioral responses: enhanced locomotion or stereotypies and facilitated acquisition of cocaine self-administration. Addict Neurosci 9:100131
pubmed: 38222942
pmcid: 10785378
Lamoureux L, Beverley J, Steiner H, Marinelli M (2024) Methylphenidate with or without fluoxetine triggers reinstatement of cocaine seeking behavior in rats. Neuropsychopharmacology 49:953–960
pubmed: 38086900
Moon C, Marion M, Thanos PK, Steiner H (2021) Fluoxetine potentiates oral methylphenidate-induced gene regulation in the rat striatum. Mol Neurobiol 58:4856–4870
pubmed: 34213723
pmcid: 8500935
Thanos PK, Robison LS, Steier J, Hwang YF, Cooper T, Swanson JM, Komatsu DE, Hadjiargyrou M, Volkow ND (2015) A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior. Pharmacol Biochem Behav 131:143–153
pubmed: 25641666
pmcid: 4461871
Thanos PK, McCarthy M, Senior D, Watts S, Connor C, Hammond N, Blum K, Hadjiargyrou M, Komatsu D, Steiner H (2023) Combined chronic oral methylphenidate and fluoxetine treatment during adolescence: effects on behavior. Curr Pharm Biotechnol 24:1307–1314
pubmed: 36306463
Senior D, McCarthy M, Ahmed R, Klein S, Lee WX, Hadjiargyrou M, Komatsu D, Steiner H, Thanos PK (2023) Chronic oral methylphenidate plus fluoxetine treatment in adolescent rats increases cocaine self-administration. Addict Neurosci 8:100127
pubmed: 38274857
pmcid: 10809890
Steiner H, Warren BL, Van Waes V, Bolaños-Guzmán CA (2014) Life-long consequences of juvenile exposure to psychotropic drugs on brain and behavior. Prog Brain Res 211:13–30
pubmed: 24968775
pmcid: 4331026
Borycz J, Zapata A, Quiroz C, Volkow ND, Ferré S (2008) 5-HT(1B) receptor-mediated serotoninergic modulation of methylphenidate-induced locomotor activation in rats. Neuropsychopharmacology 33:619–626
pubmed: 17487226
Van Waes V, Ehrlich S, Beverley JA, Steiner H (2015) Fluoxetine potentiation of methylphenidate-induced gene regulation in striatal output pathways: potential role for 5-HT1B receptor. Neuropharmacology 89:77–86
pubmed: 25218038
Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, Middlemiss DN, Dawson LA (2005) Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 510:49–57
pubmed: 15740724
Owen RT (2011) Vilazodone: a new treatment option for major depressive disorder. Drugs Today (Barc) 47:531–537
pubmed: 22013560
Cruz MP (2012) Vilazodone HCl (Viibryd): a serotonin partial agonist and reuptake inhibitor for the treatment of major depressive disorder. Pharm Ther 37:28–31
Meadows SM, Conti MM, Gross L, Chambers NE, Avnor Y, Ostock CY, Lanza K, Bishop C (2018) Diverse serotonin actions of Vilazodone reduce L-3,4‐dihydroxyphenylalanine-induced dyskinesia in hemi‐parkinsonian rats. Mov Disord 33:1740–1749
pubmed: 30485908
Altwal F, Moon C, West AR, Steiner H (2020) The multimodal serotonergic agent vilazodone inhibits L-DOPA-induced gene regulation in striatal projection neurons and associated dyskinesia in an animal model of Parkinson’s disease. Cells 9:2265
pubmed: 33050305
pmcid: 7600385
Smith S, Sergio J, Coyle M, Elder K, Centner A, Cohen S, Terry M, Lipari N, Glinski J, Wheelis E, Budrow C, Bishop C (2022) The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats. Psychopharmacology 239:2119–2132
pubmed: 35275226
Altwal F, Padovan-Neto FE, Ritger A, Steiner H, West AR (2021) Role of 5-HT1A receptor in vilazodone-mediated suppression of L-DOPA-induced dyskinesia and increased responsiveness to cortical input in striatal medium spiny neurons in an animal model of Parkinson’s disease. Molecules 26:5790
pubmed: 34641332
pmcid: 8510243
Hrabak M, Moon C, Bolaños-Guzmán CA, Steiner H (2024) Vilazodone, a selective serotonin reuptake inhibitor with diminished impact on methylphenidate-induced gene regulation in the striatum: role of 5-HT1A receptor. Mol Neurobiol 61:1907–1919
pubmed: 37807008
Steiner H (2016) Psychostimulant-induced gene regulation in striatal circuits. In: Steiner H, Tseng KY (eds) Handbook of basal ganglia structure and function. Academic Press/Elsevier, London, pp 639–672
Willuhn I, Sun W, Steiner H (2003) Topography of cocaine-induced gene regulation in the rat striatum: relationship to cortical inputs and role of behavioural context. Eur J Neurosci 17:1053–1066
pubmed: 12653981
Padovan-Neto FE, Patterson S, Voelkner NM, Altwal F, Beverley JA, West AR, Steiner H (2020) Selective regulation of 5-HT1B serotonin receptor expression in the striatum by dopamine depletion and repeated L-DOPA treatment: relationship to L-DOPA-induced dyskinesias. Mol Neurobiol 57:736–751
pubmed: 31468338
Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic, New York
Yano M, Steiner H (2005) Methylphenidate (ritalin) induces Homer 1a and zif 268 expression in specific corticostriatal circuits. Neuroscience 132:855–865
pubmed: 15837145
Van Waes V, Carr B, Beverley JA, Steiner H (2012) Fluoxetine potentiation of methylphenidate-induced neuropeptide expression in the striatum occurs selectively in direct pathway (striatonigral) neurons. J Neurochem 122:1054–1064
pubmed: 22738672
pmcid: 3423503
Van Waes V, Vandrevala M, Beverley J, Steiner H (2014) Selective serotonin re-uptake inhibitors potentiate gene blunting induced by repeated methylphenidate treatment: Zif268 versus Homer1a. Addict Biol 19:986–995
pubmed: 23763573
Nestler EJ (2001) Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2:119–128
pubmed: 11252991
Sahli ZT, Banerjee P, Tarazi FI (2016) The preclinical and clinical effects of vilazodone for the treatment of major depressive disorder. Expert Opin Drug Discov 11:515–523
pubmed: 26971593
pmcid: 4841022
Samaha AN, Robinson TE (2005) Why does the rapid delivery of drugs to the brain promote addiction? Trends Pharmacol Sci 26:82–87
pubmed: 15681025
Yen TT, Fuller RW (1992) Preclinical pharmacology of fluoxetine, a serotonergic drug for weight loss. Am J Clin Nutr 55(Suppl):177S–180S
pubmed: 1728830
Goldstein DJ, Potvin JH (1994) Long-term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 60:647–657
pubmed: 7942569
Cheer SM, Goa KL (2001) Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs 61:81–110
pubmed: 11217873
Hurd YL, Herkenham M (1993) Molecular alterations in the neostriatum of human cocaine addicts. Synapse 13:357–369
pubmed: 7683144
Frankel PS, Alburges ME, Bush L, Hanson GR, Kish SJ (2008) Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Neuropharmacology 55:41–46
pubmed: 18538358
pmcid: 2577569
Nestler EJ, Carlezon WAJ (2006) The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59:1151–1159
pubmed: 16566899
Shippenberg TS, Zapata A, Chefer VI (2007) Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 116:306–321
pubmed: 17868902
pmcid: 2939016
Steiner H, Gerfen CR (1998) Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp Brain Res 123:60–76
pubmed: 9835393
Hyman SE, Nestler EJ (1996) Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 153:151–162
pubmed: 8561194
Butelman ER, Yuferov V, Kreek MJ (2012) κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci 35:587–596
pubmed: 22709632
pmcid: 3685470